Gemcitabine with Cisplatin or Epirubicin for Lung Cancer
Author Information
Author(s): Wachters F M, van Putten J W G, Kramer H, Erjavec Z, Eppinga P, Strijbos J H, de Leede G P J, Boezen H M, de Vries E G E, Groen H J M
Primary Institution: University Hospital Groningen
Hypothesis
The study aims to compare the efficacy and safety of gemcitabine in combination with either cisplatin or epirubicin in patients with advanced non-small-cell lung cancer.
Conclusion
The efficacy of epirubicin and cisplatin both combined with gemcitabine is not significantly different in terms of progression-free survival and tumor response rates.
Supporting Evidence
- Patients receiving cisplatin had a median overall survival of 43 weeks.
- Patients receiving epirubicin had a median overall survival of 36 weeks.
- Progression-free survival was similar between both treatment arms.
Takeaway
Doctors tested two types of chemotherapy for lung cancer to see which one works better, but both did about the same job.
Methodology
Patients were randomized to receive either cisplatin or epirubicin both with gemcitabine, and the study evaluated progression-free survival as the primary endpoint.
Potential Biases
Potential bias due to the exclusion of elderly patients with poor performance status or comorbidity.
Limitations
The study did not find significant differences in overall survival, and the power analysis was not performed to detect differences in overall survival.
Participant Demographics
240 patients, median age 60, with a mix of male and female participants.
Statistical Information
P-Value
0.121
Confidence Interval
95% CI, 37–55 for CG arm; 95% CI, 28–45 for EG arm
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website